Article citationsMore>>

Otsuka Pharmaceutical Co. (2015) Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY— ABILIFY for Extended-Release Injectable Suspension, for Intramuscular Use—Indicated for Schizophrenia. https://www.otsuka.co.jp/en/company/release/2015/0326_03.html

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top